PH12022550056A1 - Dll3-targeting antibodies and uses thereof - Google Patents

Dll3-targeting antibodies and uses thereof

Info

Publication number
PH12022550056A1
PH12022550056A1 PH1/2022/550056A PH12022550056A PH12022550056A1 PH 12022550056 A1 PH12022550056 A1 PH 12022550056A1 PH 12022550056 A PH12022550056 A PH 12022550056A PH 12022550056 A1 PH12022550056 A1 PH 12022550056A1
Authority
PH
Philippines
Prior art keywords
dll3
antibodies
targeting antibodies
immunoglobulin
delta
Prior art date
Application number
PH1/2022/550056A
Other languages
English (en)
Inventor
David Andrew
Xinlei Chen
Abdul Khan
Jason Lewis
Ivo Lorenz
John T Poirier
Charles Rudin
Original Assignee
Memorial Sloan Kettering Cancer Center
Tri Inst Therapeutics Discovery Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center, Tri Inst Therapeutics Discovery Inst filed Critical Memorial Sloan Kettering Cancer Center
Publication of PH12022550056A1 publication Critical patent/PH12022550056A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PH1/2022/550056A 2019-07-11 2020-07-08 Dll3-targeting antibodies and uses thereof PH12022550056A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962872915P 2019-07-11 2019-07-11
PCT/US2020/041282 WO2021007371A1 (en) 2019-07-11 2020-07-08 Dll3-targeting antibodies and uses thereof

Publications (1)

Publication Number Publication Date
PH12022550056A1 true PH12022550056A1 (en) 2023-04-12

Family

ID=74115317

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2022/550056A PH12022550056A1 (en) 2019-07-11 2020-07-08 Dll3-targeting antibodies and uses thereof

Country Status (13)

Country Link
US (1) US12441789B2 (cg-RX-API-DMAC7.html)
EP (1) EP3997127A4 (cg-RX-API-DMAC7.html)
JP (2) JP7661299B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220034167A (cg-RX-API-DMAC7.html)
CN (3) CN119080930A (cg-RX-API-DMAC7.html)
AU (1) AU2020310894A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022000216A2 (cg-RX-API-DMAC7.html)
CA (1) CA3146566A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022001195A2 (cg-RX-API-DMAC7.html)
IL (1) IL289585A (cg-RX-API-DMAC7.html)
MX (1) MX2022000325A (cg-RX-API-DMAC7.html)
PH (1) PH12022550056A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021007371A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2718257T3 (cg-RX-API-DMAC7.html) * 2014-05-30 2018-04-14
US12441789B2 (en) * 2019-07-11 2025-10-14 Memorial Sloan Kettering Cancer Center DLL3-targeting antibodies and uses thereof
EP4277665A1 (en) * 2021-01-13 2023-11-22 Memorial Sloan Kettering Cancer Center Anti-dll3 antibody-drug conjugate
CN117425501A (zh) * 2021-01-13 2024-01-19 纪念斯隆凯特琳癌症中心 抗体-吡咯并苯二氮䓬衍生物缀合物
US20240239878A1 (en) * 2021-05-08 2024-07-18 Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. Binding molecule against dll3 and use thereof
CA3230627A1 (en) * 2021-09-02 2023-03-09 Memorial Sloan-Kettering Cancer Center Antigen recognizing receptors targeting dll3 and uses thereof
WO2023034557A1 (en) * 2021-09-02 2023-03-09 Memorial Sloan-Kettering Cancer Center Radioligand binding to anti-dll3 antibodies for pretargeted pet imaging and therapeutic uses thereof
JP2024534892A (ja) * 2021-09-02 2024-09-26 メモリアル スローン ケタリング キャンサー センター 抗dll3抗体及びその使用
TW202346346A (zh) * 2021-12-23 2023-12-01 大陸商江蘇恆瑞醫藥股份有限公司 抗dll3抗體、其抗體-藥物偶聯物及其醫藥用途
IL314678A (en) 2022-02-27 2024-10-01 Boehringer Ingelheim Int Bispecific antibodies against cd277 and a tumor-antigen
CN116003628B (zh) * 2022-08-15 2026-08-04 南京博安生物技术有限公司 靶向人dll3抗原的全人源特异性嵌合抗原受体及其应用
WO2025184421A1 (en) * 2024-02-28 2025-09-04 Juno Therapeutics, Inc. Chimeric antigen receptors and antibodies specific for delta-like ligand 3 (dll3) and related methods

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1838968A (zh) 2003-08-08 2006-09-27 艾伯吉尼斯公司 针对甲状旁腺激素(pth)之抗体和其用途
EP2094307A4 (en) * 2006-11-08 2015-08-26 Macrogenics West Inc TES7 AND THEREO BINDING ANTIBODIES
PL2530091T3 (pl) 2010-01-29 2018-08-31 Chugai Seiyaku Kabushiki Kaisha Przeciwciało przeciwko dll3
EP2598532B1 (en) 2010-07-30 2017-07-12 Gianluca Moroncini Epitopes of the human pdgf receptor able to bind human auto-antibodies, antibodies and uses thereof
ES2886123T3 (es) * 2012-01-31 2021-12-16 Regeneron Pharma Anticuerpos anti-asic1 y usos de los mismos
CN104520324A (zh) * 2012-02-24 2015-04-15 施特姆森特Rx股份有限公司 Dll3调节剂及其使用方法
EP3107576A4 (en) * 2014-02-21 2017-09-06 Abbvie Stemcentrx LLC Anti-dll3 antibodies and drug conjugates for use in melanoma
AR101669A1 (es) 2014-07-31 2017-01-04 Amgen Res Munich Gmbh Constructos de anticuerpos para cdh19 y cd3
RS61010B1 (sr) * 2014-11-20 2020-11-30 Hoffmann La Roche Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije protiv folr1 i cd3
US12441789B2 (en) * 2019-07-11 2025-10-14 Memorial Sloan Kettering Cancer Center DLL3-targeting antibodies and uses thereof

Also Published As

Publication number Publication date
KR20220034167A (ko) 2022-03-17
EP3997127A4 (en) 2023-08-23
JP7661299B2 (ja) 2025-04-14
CN118955717A (zh) 2024-11-15
WO2021007371A1 (en) 2021-01-14
JP2025156278A (ja) 2025-10-14
BR112022000216A2 (pt) 2022-05-17
CN119080930A (zh) 2024-12-06
AU2020310894A1 (en) 2022-02-03
US12441789B2 (en) 2025-10-14
EP3997127A1 (en) 2022-05-18
CO2022001195A2 (es) 2022-03-08
CA3146566A1 (en) 2021-01-14
CN114341182B (zh) 2024-09-10
IL289585A (en) 2022-03-01
US20220348648A1 (en) 2022-11-03
MX2022000325A (es) 2022-03-25
CN114341182A (zh) 2022-04-12
JP2022540611A (ja) 2022-09-16

Similar Documents

Publication Publication Date Title
WO2020172621A8 (en) Cd33 antibodies and methods of using the same to treat cancer
ZA202206437B (en) Claudin18.2 binding moieties and uses thereof
WO2022032003A3 (en) Anti-claudin 18.2 antibodies and uses thereof
ZA202308021B (en) Anti-ctla4 antibodies and methods of making and using the same
AU2018338322A1 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
SA519402358B1 (ar) Ccr7 مترافقات عقار جسم مضاد لـ
NZ782442A (en) Antibodies that bind cd39 and uses thereof
EP4389226A3 (en) Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
MX2022000325A (es) Anticuerpos dirigidos contra dll3 y usos de los mismos.
NZ734803A (en) Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
ZA202201464B (en) Anti-tigit antibodies and application thereof
IL163902A0 (en) Antibodies against cancer antigen tmeff2 and uses thereof
AU2018253589A1 (en) Antibodies, pharmaceutical compositions and uses thereof
MX2010001237A (es) Nuevos anticuerpos.
MX2023009715A (es) Anticuerpo de dominio individual biespecífico contra el ligando de muerte programada (pd-l1) y el cúmulo de diferenciación 47 (cd47) y uso del mismo.
PH12021553197A1 (en) Anti-cd47 antibodies and uses thereof
WO2022108976A3 (en) Anti-gpa33 multi-specific antibodies and uses thereof
MX2025006929A (es) Anticuerpos contra la proteína 1 que contiene dominio de cub (cdcp1) y usos de estos
MX2025003153A (es) Anticuerpos anti-ccr8
MX2022005718A (es) Anticuerpos tmem219 y usos terapeuticos de los mismos.
MX2009008754A (es) Anticuerpos novedosos contra igf-1r.
WO2024031009A3 (en) Anti-cd24 antibodies and uses thereof
MX2021008453A (es) Formulaciones de anticuerpos que se unen a cd137 humano y usos de los mismos.
WO2022081443A3 (en) Anti-psma antibodies and uses thereof